ARTICLE | Clinical News
Tesofensine: Phase I data
May 18, 2009 7:00 AM UTC
Data from the double-blind, placebo- and active-controlled, Canadian Phase I TIPO-5 trial in 44 healthy recreational stimulant users showed that 1-9 mg oral tesofensine met the primary endpoint by dem...